Regulatory Efficiency: Accelerating the Start-Up Phase for UK Clinical Studies
The regulatory environment surrounding clinical research in the United Kingdom is designed for efficiency and transparency, aiming to significantly reduce the time required to initiate and begin recruiting for a clinical study. The primary bodies involved, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), work collaboratively to streamline...
0 Commentarii 0 Distribuiri 11 Views 0 previzualizare